SCHEMBL1915298

SCHEMBL1915298

NC(=O)CCCC(C(N)=O)(c1ccc(C=O)cc1)c1ccc(C=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.39
CHRM2 P08172 3/20 0.36
CHRM3 P20309 3/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 1/20 0.36
CHRM1 P11229 1/20 0.36
KCNH2 Q12809 1/20 0.36
PARP10 Q53GL7 1/20 0.36
PARP3 Q9Y6F1 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
ALDH1A1 P00352 3/20 0.35
ALDH5A1 P51649 1/20 0.34
ABAT P80404 1/20 0.34
CYP1A2 P05177 2/20 0.31
CYP2A6 P11509 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KCNN4 O15554 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1915245 0.95 KMT2A (0.41) KMT2ACHRM2CHRM3LMNACYP2D6
SCHEMBL1915600 0.94 KMT2A (0.41) KMT2ACHRM2CHRM3LMNACYP2D6
SCHEMBL28118917 0.81 CHRM3 (0.42) CHRM2CHRM3LMNACYP2D6CHRM1
SCHEMBL1916611 0.81 PARP10 (0.39) KMT2ACHRM2CHRM3LMNACYP2D6
SCHEMBL28063826 0.80 CHRM2 (0.41) CHRM2CHRM3LMNACYP2D6CHRM1
SCHEMBL4138872 0.80 CHRM3 (0.54) KMT2ACHRM2CHRM3LMNACYP2D6
SCHEMBL1915397 0.77 KMT2A (0.39) KMT2AEPHX2NR1H4ALDH1A1ALDH5A1
SCHEMBL28063823 0.77 KIF11 (0.40) CHRM2CHRM3LMNACYP2D6CHRM1
SCHEMBL28118919 0.75 CHRM2 (0.40) CHRM2CHRM3LMNACYP2D6CHRM1
SCHEMBL20543316 0.74 SMN1; SMN2 (0.45) KMT2AKDM4EEPHX2NR1H4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018140-A1 N-BRIDGED POLYNITRONS AND THE USE THEREOF AS CROSS-LINKING AGENTS, IN PARTICULAR IN COATING MATERIALS AND ADHESIVES DICKMEIS MARCUS (DE) 2013-01-17 US disclosed
EP-2516531-A1 N-BRIDGED POLYNITRONS AND THE USE THEREOF AS CROSS-LINKERS, IN PARTICULAR IN COATING MATERIALS AND ADHESIVES Dickmeis, Marcus (DE) 2012-10-31 EP disclosed
EP-2516532-A2 POLYOXAZIRIDINES AND USE THEREOF AS A CROSS-LINKING AGENT, ESPECIALLY IN COATING MATERIALS AND ADHESIVES Dickmeis, Marcus (DE) 2012-10-31 EP disclosed
WO-2011085793-A2 POLYOXAZIRIDINES AND USE THEREOF AS A CROSS-LINKING AGENT, ESPECIALLY IN COATING MATERIALS AND ADHESIVES DICKMEIS MARCUS (DE) 2011-07-21 WO disclosed
WO-2011076392-A1 N-BRIDGED POLYNITRONS AND THE USE THEREOF AS CROSS-LINKERS, IN PARTICULAR IN COATING MATERIALS AND ADHESIVES DICKMEIS MARCUS (DE) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018140-A1 N-BRIDGED POLYNITRONS AND THE USE THEREOF AS CROSS-LINKING AGENTS, IN PARTICULAR IN COATING MATERIALS AND ADHESIVES PNN, PARN, NCLN KMT2A 631/4885CHRM2 974/4885CHRM3 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.